Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys

This publication has 59 references indexed in Scilit:

• C and V proteins of Sendai virus target signaling pathways leading to IRF-3 activation for the negative regulation of interferon-β production
  Virology, 2004
• The Amino-Terminal Extensions of the Longer Sendai Virus C Proteins Modulate pY701-Stat1 and Bulk Stat1 Levels Independently of Interferon Signaling
  Journal of Virology, 2003
• All Four Sendai Virus C Proteins Bind Stat1, but only the Larger Forms also Induce Its Mono-ubiquitination and Degradation
  Virology, 2002
• Sequence Analysis of the Washington/1964 Strain of Human Parainfluenza Virus Type 1 (HPIV1) and Recovery and Characterization of Wild-Type Recombinant HPIV1 Produced by Reverse Genetics
  Virus Genes, 2002
• Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States
  The Pediatric Infectious Disease Journal, 2001
• Y2, the Smallest of the Sendai Virus C Proteins, Is Fully Capable of both Counteracting the Antiviral Action of Interferons and Inhibiting Viral RNA Synthesis
  Journal of Virology, 2001
• Human Parainfluenza Virus Type 3 (PIV3) Expressing the Hemagglutinin Protein of Measles Virus Provides a Potential Method for Immunization against Measles Virus and PIV3 in Early Infancy
  Journal of Virology, 2000
• A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3
  Vaccine, 1999
• Knockout of the Sendai virus C gene eliminates the viral ability to prevent the interferon‐α/β‐mediated responses
  FEBS Letters, 1999
• The P genes of human parainfluenza virus type 1 clinical isolates are polycistronic and microheterogenous
  Virology, 1992